- Description
| Specificity Profile | More Information |
 | The specificity of VEGF-A Monoclonal Antibody (CSB0068) was tested on the Membrane Proteome Array™ and shown to be specific for human VEGF-A. The Membrane Proteome Array™ contains 6,000 different human membrane proteins, each expressed in unfixed human cells to ensure native conformation and post-translational modifications. The Membrane Proteome Array™ represents the industry standard for determining the binding specificity of antibodies and other protein ligands. |
| Application | Conditions | Recommended Concentration |
| Flow Cytometry, Extracellular | Live, Unpermeabilized | 1 µg/ml |
 | JS-1 cells transiently transfected with human VEGF-A were stained with VEGF-A Monoclonal Antibody (CSB0068) (green) or isotype control antibody (gray), followed by AlexaFluor 647-conjugated anti-Mouse IgG secondary antibody. JS-1 cells transiently transfected with an empty control vector were also stained with VEGF-A Monoclonal Antibody (CSB0068) (blue). | |
| Application | Conditions | Recommended Concentration |
| Immunofluorescence, Extracellular | Fixed 4% paraformaldehyde | 1 µg/ml |
 | (A) COS-7 cells transiently transfected with human VEGF-A were stained with VEGF-A Monoclonal Antibody (CSB0068) followed by AlexaFluor 647 anti-Mouse IgG secondary antibody (red) and DAPI (blue). (B) COS-7 cells transiently transfected with an empty control vector stained with VEGF-A Monoclonal Antibody. (C) Isotype control: COS-7 cells transfected with human VEGF-A and stained with control MAb. | |
| Application | Conditions | Recommended Concentration |
| Immunofluorescence, Intracellular | Fixed 4% paraformaldehyde, Permeabilized 0.1% Triton X-100 | 1 µg/ml |
 | (A) COS-7 cells transiently transfected with human VEGF-A were permeabilized and stained with VEGF-A Monoclonal Antibody (CSB0068) followed by AlexaFluor 647 anti-Mouse IgG secondary antibody (red) and DAPI (blue). (B) COS-7 cells transiently transfected with an empty control vector stained with VEGF-A Monoclonal Antibody. (C) Isotype control: COS-7 cells transfected with human VEGF-A and stained with control MAb. | |
CSB VeRSaMAbs:
We produce and validate all our monoclonal antibodies in-house so that you can confidently choose the right antibody for your assay. All antibodies are VALIDATED for common applications, RECOMBINANT for batch-to-batch consistency, and SPECIFIC in binding to only your target.
| Target | VEGF-A |
| Target Aliases | VPF, VEGF, MVCD1 |
| Isotype | Mouse IgG2a |
| Membrane Proteome Specificity | Monospecific for 6,000 membrane proteins tested |
| Species Reactivity | Human (others untested) |
| Fc Modifications | C-terminal Avitag, disabled Fc-gamma receptor binding |
| Source | Recombinant CHO expression; purified by Protein A chromatography |
| Formulation | Endotoxin Free PBS pH 7.4, sterile-filtered |
| Concentration | 1 mg/ml |
Stable for 12 months from date of receipt when stored at 4°C. Avoid repeated freeze-thaw cycles.
VEGF-A is a member of the PDGF/VEGF growth factor family. Specifically, VEGF-A is a disulfide-linked homodimer that binds heparin. VEGF-A is a secreted protein involved in endothelial cell proliferation and migration, angiogenesis, and vasculogenesis. Increased expression is associated with SARS-CoV-2 and POEMS syndrome as well as many tumors, and allelic variants are associated with microvascular complications of diabetes 1 and atherosclerosis. (NCBI Gene: 7422, UniProtKB/Swiss-Prot: P15692). Other names: VPF, VEGF, MVCD1
